Vernalis PLC: AGM Statement WINNERSH, UNITED

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
507
Vernalis PLC: AGM Statement

WINNERSH, UNITED KINGDOM--(Marketwired - Dec 14, 2017) - Vernalis PLC ( LSE : VER )

14 December 2017 LSE: VER

AGM Statement

Tuzistra ® XR prescriptions continue to grow steadily, despite a reduction in narcotic prescribing

Vernalis plc ("Vernalis" or the "Company") provides an update ahead of its Annual General Meeting ("AGM") being held today at 10.30 am at the offices of Covington & Burling, 265 Strand, London WC2R 1BH.

Highlights

  • Tuzistra ® XR prescriptions continue to grow steadily, up 85% on prior year (1 July to 1 Dec) - With c.70% of 2017/18 cough cold season remaining, Tuzistra ® XR needs to see an acceleration in prescription growth to achieve the annual guidance of 105,000-115,000 prescriptions - Next update: end of Q1 2018 - in conjunction with interim results release
  • CCP-06, our non-narcotic cough cold product candidate, continues to progress
  • CCP-07 and CCP-08 NDAs remain on track for approval during 2018/19 financial year
  • Research business continues to perform well

Ian Garland, CEO of Vernalis commented : "We are encouraged by the steady growth in Tuzistra ® XR prescriptions, despite the general negativity, in the US, surrounding the use of narcotic-based drugs. Whilst we need to see acceleration in prescription growth to achieve our total prescription market guidance of a threefold increase in prescription volume, we are early in the cough cold season and the US commercial team is executing a disciplined plan to accelerate growth over the coming months."

Tuzistra ® XR and the cough cold franchise

Tuzistra ® XR scripts grow 85%

Tuzistra ® XR prescriptions for the 22 weeks from 1 July 2017 to 1 December 2017, the latest weekly data available, are up approximately 85% on the equivalent 22 week period of the prior year. Although we have seen steady growth, this growth will need to accelerate in the four months to March 2018, when typically almost half of the annual cough cold prescriptions are written (2016/17 approximately 49% of annual total), if we are to achieve our target growth of 200% over the prior year. We will provide a further update at the end of Q1 2018 when we announce our interim results for the six months to 31 December 2017.

Total cough cold market opportunity remains intact, however narcotic segment continues to decline

The growth in Tuzistra ® XR prescriptions seen in the first 22 weeks of 2017/18 is against a background of a continuing decline in the narcotic portion of the prescription cough cold market. Year-to-date, the combined prescribing of codeine and hydrocodone-based cough cold products is down 13% compared to the same period in the prior year, which itself was down 14% compared to 2015/16. Over the past two years, the combined prescribing of codeine and hydrocodone cough products has fallen by 25%. This decline in prescribing reflects continued public focus on the level of usage of opiate based products that are prescribed to treat pain. Although the use of opiates in a short term acute setting to treat cough cold is not the principal area of concern, we are still seeing a significant impact on prescribing.

In addition to this decline in the level of narcotic prescribing, restrictions on the size of narcotic prescriptions have also been introduced by some US States, health insurance plans and physicians. This has resulted in a decline in the average size of a Tuzistra ® XR prescription from approximately 160 mL in the prior year to approximately 145-150 mL in the current year-to-date. This decline in prescription size will have an impact on the net sales value of each Tuzistra ® XR prescription.

CCP-06, our non-narcotic cough cold product continues to progress and will allow us to fully exploit potential of franchise

The prescription cough cold market comprises both narcotic and non-narcotic based products and the dynamics highlighted above only impact the narcotic portion. This is important because of the mix of cough cold products in our portfolio. We have one non-narcotic product in development (CCP-06) and our two most advanced pipeline products (CCP-07 and CCP-08), like Tuzistra ® XR, are both targeting the narcotic portion of the market but include additional active ingredients that can extend their market reach.

CCP-07/08 NDAs still on track for approval during 2018/19 financial year

In April 2017 and August 2017, we announced that we had received Complete Response Letters (CRLs) for CCP-07 and CCP-08 respectively and would provide further information related to the issues raised by the FDA and the implications on the timing of their re-submissions and potential approvals. We are now able to provide updated information regarding these CRLs.

In early 2017, FDA undertook an inspection at Tris and identified certain non-product related issues needed to be addressed. Given the issues identified, FDA determined that it was unable to approve CCP-07 on its 20 April 2017 PDUFA date and instead issued a CRL, indicating that these issues needed to be addressed before re-submission of the NDA could occur. On 4 August 2017, although Tris had made good progress in addressing the issues, FDA was unable to approve the CCP-08 NDA and issued a CRL for that product. The CRL for CCP-08 indicated that the FDA wanted evidence that the issues identified in its inspection at Tris did not impact the CCP-08 NDA. This evidence includes manufacturing new batches of CCP-08 and could require repeating the pivotal bio-equivalence studies on which approval was sought.

Tris is working diligently to address the issues raised by FDA and specifically as they relate to the NDAs for CCP-07 and CCP-08. This includes the support of external expert consultants and regular discussions with FDA. We continue to believe that both NDAs are approvable and could potentially be resubmitted and subsequently approved during our 2018/19 financial year.

Moxatag ®

We continue to progress qualification of a new supplier of Moxatag ® and expect to be back in supply during 2018. We continue to focus on increasing pharmacy stocking since its re-launch in September and will provide a more detailed update when we announce our interim results at the end of Q1 2018.

Research Business continues to perform well

The research business continues to perform to plan having secured a EUR 1m milestone from the third collaboration with Servier (as recently announced) as well as two new collaborations, including one recently announced with Daiichi Sankyo.

Cash position is in line with expectations

The Company's unaudited cash position (including cash and cash equivalents and held to maturity assets), remains strong and at 11 December 2017, was £48.9 million. The cash position has been negatively impacted by the weakening of the US dollar since 30 June 2017, with a significant proportion of our cash denominated in that currency.

No additional material information or updates on trading will be given at Vernalis' AGM today. The presentation to be given will be available on the company website after the AGM.

-- ends --

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement this inside information is now considered to be in the public domain.

Enquiries
 
Vernalis plc: +44 (0) 118 938 0015
Ian Garland, Chief Executive Officer  
David Mackney, Chief Financial Officer  
   
Canaccord Genuity Limited (Nominated Adviser and Joint Broker): +44 (0) 20 7523 8000
Henry Fitzgerald-O'Connor  
Emma Gabriel  
   
Shore Capital (Joint Broker): +44 (0) 20 7408 4090
Mark Percy  
Toby Gibbs  
   
FTI Consulting: +44 (0) 20 3727 1000
Ben Atwell  
Simon Conway  
Stephanie Cuthbert  
   
Stern Investor Relations, Inc: + 1 212 362 1200
Stephanie Ascher  
Jane Urheim  
 

Notes to Editors

About Vernalis Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has three approved products: Tuzistra ® XR targeting the US prescription cough-cold market; Moxatag ® , a once-daily formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focused on the US prescription cough-cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier, and Tris.

For further information about Vernalis, please visit www.vernalis.com .

Vernalis Forward-Looking Statement This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its NCE pipeline, the Company's ability to successfully commercialise its cough-cold products and Moxatag ® through its own sales force, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of Tuzistra ® XR, Moxatag ® , frovatriptan and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.

Contact: RNS Customer Services 0044-207797-4400 rns@londonstockexchange.com http://www.rns.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RAN Rebound Gains Speed, but 2027 Still Looks Flat

Updated Category News Views 101

Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...

Continue Reading
Mace Consult Bets on Sawaya for Americas Expansion

Updated Category News Views 79

Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...

Continue Reading
Sungrow Puts Storage Safety and Deployment on Display

Updated Category News Views 129

Fire-test footage is not usually the thing that grabs a room in Las Vegas, but Sungrow made it the centerpiece at RE+ 2026 for a reason. Energy storage has no shortage of glossy promises; what it needs is proof that equipment can handle the ugly stuff. Sungrow used the show to pitch a broader North American lineup, yet the PowerTitan 3.0 battery system and its large-scale...

Continue Reading
V2’s FOAS Bets on Candid Ad Sales Operator Dialogue

Updated Category News Views 99

Ad sales rarely gets fixed by another ballroom panel, and V2 seems to know it. Its new Future of Ad Sales, or FOAS, forum is built around a simpler premise: put senior operators in a small room, keep vendors and conference theatrics out of the way, and let people compare the ugly real-world details of running revenue machines. Announced November 19, 2026, FOAS is an...

Continue Reading
Vanguard's Digital Win Matters More Than a Trophy

Updated Category News Views 104

A wealth manager’s website rarely earns applause, but a bad one can sure as hell lose trust fast. Vanguard’s move to No. 1 from No. 3 in the 2025 ranking for advised-investor website satisfaction is worth noticing because it hits the unglamorous part of wealth management that clients actually live with: checking accounts, understanding a plan, moving cash, and...

Continue Reading
Envision’s COP31 Pitch Hinges on Grid Execution, Not Targets

Updated Category News Views 93

A 2,500 GW traffic jam is a rotten place to park climate ambition. Envision Energy used COP31 in Antalya to make the more useful point: clean-power targets mean very little if grids cannot connect, balance and dispatch the electricity. Kane Xu’s message was not another round of flag-waving promises. It was an argument that the constraint has shifted from wanting...

Continue Reading
JDEnergy's RE+ Push Meets a Grid Hungry for Storage

Updated Category News Views 33

Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...

Continue Reading
Linq's $90M Bet on the Infrastructure Behind AI Agents

Updated Category News Views 218

Ninety million dollars just landed on the least glamorous part of the AI-agent rush: the pipes. Linq, the San Francisco private company, announced the round on November 18, 2026, led by Andreessen Horowitz, with returning backing from TQ Ventures, Mucker Capital and Abstract, plus new money from Anthos and Left Lane Capital. Ben Horowitz is joining the board. That is a...

Continue Reading
Tigerlily Takes Its Advocacy Model to Ovarian Cancer

Updated Category News Views 136

Ovarian cancer has a nasty habit of hiding behind symptoms people are taught to shrug off. Persistent bloating or pelvic pain can look like any number of ordinary problems, and that ambiguity is exactly why practical, trusted education matters. Tigerlily Foundation's new ovarian cancer initiative is not a flashy breakthrough claim. It is a grounded attempt to help women...

Continue Reading
Mindgruve's Tech Hire Puts Sightline Growth in Focus

Updated Category News Views 23

Agency technology hires usually land with all the thunder of a stapler dropping, but this one deserves a closer look. Mindgruve has named Steve Terjeson vice president of technology, handing a former WPP Choreograph executive the job of leading its software development and data engineering teams. The assignment is not vague: push AI innovation, make the proprietary...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating 15 Years of Animal Rescue Corps' Impact

Updated Category News Views 307

Animal Rescue Corps Commemorates 15 Years of Impact Animal Rescue Corps (ARC), a dedicated national nonprofit organization, is excited to celebrate 15 remarkable years of rescuing animals and advocating for their protection. This milestone is not just a reflection of the past but a commitment to continue fighting for animals in need. To honor this achievement, ARC warmly...

Continue Reading
Investigating Investor Claims: Atara Biotherapeutics Update

Updated Category News Views 184

Investor Investigations into Atara Biotherapeutics Recent developments have led to significant interest from investors regarding Atara Biotherapeutics, Inc. (NASDAQ: ATRA). Allegations of possible securities fraud have prompted Pomerantz LLP to investigate the circumstances surrounding the company's practices. If you hold shares in Atara, it's crucial to stay informed...

Continue Reading
Systech's Remarkable 40-Year Journey in Pharma Packaging

Updated Category News Views 329

Systech Celebrates 40 Years of Industry Excellence Marking four decades of innovation, Systech has emerged as a key player in the field of packaging and serialization for the pharmaceutical industry. The company has developed a unique platform that alleviates the common frustrations of working with multiple vendors, providing a comprehensive solution that enhances...

Continue Reading
Empowering Black Artists: The BMAC LIVE Accelerator Initiative

Updated Category News Views 134

The Black Music Action Coalition Launches BMAC LIVE Accelerator Program The Black Music Action Coalition (BMAC) has officially announced the exciting return of its BMAC LIVE Accelerator Program. This initiative is designed to empower Black artists and professionals in the music industry by providing essential resources, training, and mentorship opportunities. BMAC...

Continue Reading
Imperial Petroleum Announces Series A Preferred Share Dividend

Updated Category News Views 212

Imperial Petroleum Inc. Declares Dividend on Series A Preferred Shares ATHENS, Greece – Imperial Petroleum Inc. (NASDAQ: IMPP), a prominent player in the maritime shipping industry, recently made headlines with the announcement of a dividend of $0.546875 per share on its 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock. This dividend is notably payable to...

Continue Reading